von Tobias Borgers | Aug 24, 2019 | Glaxo
Issued: London UK GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive headline results from the pivotal DREAMM-2 open-label, randomised study of two doses of belantamab mafodotin (GSK2857916). The 196 patients in the trial had relapsed multiple myeloma, were...
von Tobias Borgers | Aug 23, 2019 | Glaxo
Issued: London, UK ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive headline results from its global phase III ATLAS-2M study of the investigational, long-acting,...
von Tobias Borgers | Aug 18, 2019 | Glaxo
Issued: London UK – LSE Announcement TESARO, an oncology-focused business acquired by GlaxoSmithKline plc (LSE/NYSE: GSK), announced today the presentation of data from the Phase 1/2 GARNET study evaluating dostarlimab in women with recurrent or advanced endometrial...
von Tobias Borgers | Jul 29, 2019 | Glaxo
Issued: London, UK ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for...
von Tobias Borgers | Jul 23, 2019 | Glaxo
Issued: London, UK London, UK, 22 July 2019 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 96 results from the phase III BRIGHTE study of investigational...
